Navigation Links
InterMune to Release Third Quarter Financial Results on November 5
Date:10/29/2009

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2009 financial results on Thursday, November 5, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 37626791. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 37626791.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline,
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release Second Quarter Financial Results on August 6
5. InterMune to Present at Goldman Sachs Healthcare Conference
6. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
7. InterMune to Release First Quarter Financial Results on April 30
8. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
9. InterMune to Present at Canaccord Adams Hepatitis C Conference
10. InterMune to Present at Citis 4th Annual Biotech Day
11. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 06, 2015 Global Specimen Solutions, ... focused on specimen management and informatics, announced today ... Specimen Solutions, Inc. is excited to catapult our ... that will further enhance our proprietary informatics tools ... specimen research. GSS has proved rapid market uptake ...
(Date:3/6/2015)... 6, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... that John Poyhonen , the Company,s President and ... Vice President and Chief Financial Officer, will present an ... Wednesday, March 11, at 2:00 p.m. Eastern Time (11:00 ...
(Date:3/6/2015)... 2015 Anton Paar has released an ... utilizing laboratory refractometers. Sodium hydroxide (NaOH, also known ... a variety of products including pretzels, colored fabrics, soap ... of the chemical industry; its applications range from the ... everything in between. NaOH is used in the ...
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6
... 2009) will feature OpenClinica in a special workshop titled "Open Source ... ... Porto, Portugal (PRWEB) January 8, 2009 -- OpenClinica will be ... Health Informatics (HEALTHINF 2009) January 14-17, 2009 in Porto, Portugal. The ...
... January 7, 2008 Researchers from Harvard University and ... first time, a repulsive quantum mechanical force that could be ... applications. , The study, led by Federico Capasso, Robert L. ... and Applied Science (SEAS), will be published as the January ...
... 7 Amgen (Nasdaq: AMGN ) will present ... 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at ... Chairman and CEO Kevin Sharer will present at the conference. ... Internet and can be accessed from Amgen,s Web site, ...
Cached Biology Technology:OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal 2Researchers measure elusive repulsive force from quantum fluctuations 2
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... DCResearchers at the Center for Neuroscience Research ... two major types of signaling pathways activated during brain ... Notch pathwayoperate together to determine how many and which ... repair in developing and adult brains. This knowledge may ...
... Cancer Epidemiology (LACE) study, 1,897 participants diagnosed with early-stage ... average 2 years post-breast cancer diagnosis were evaluated for ... and death. The women, who were generally light ... The study reported an increase in risk of ...
... there,s a new reason to grab a glass of milk when ... American Journal of Clinical Nutrition . In a 2-year weight loss ... milk. Israeli researchers found that adults who drank the most milk ... levels at 6 months, lost more weight after 2 years than ...
Cached Biology News:Discovery of key pathway interaction may lead to therapies that aid brain growth and repair 2New study finds milk drinkers may have a healthy weight advantage 2
Topoisomerase I...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: